Jazz Pharmaceuticals Public
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals Public's revenues will grow 61.1% and EPS will expand 38.5%.
The average estimate for revenue is $208.7 million. On the bottom line, the average EPS estimate is $1.51.
Last quarter, Jazz Pharmaceuticals Public booked revenue of $196.2 million. GAAP reported sales were 91% higher than the prior-year quarter's $102.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at $1.37. GAAP EPS of $0.71 for Q1 were 48% higher than the prior-year quarter's $0.48 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 86.9%, 680 basis points worse than the prior-year quarter. Operating margin was 38.8%, 330 basis points worse than the prior-year quarter. Net margin was 22.1%, 490 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $853.3 million. The average EPS estimate is $6.18.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 252 members out of 317 rating the stock outperform, and 65 members rating it underperform. Among 83 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 70 give Jazz Pharmaceuticals Public a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $71.36.
- Add Jazz Pharmaceuticals Public to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Stocks That Are Absurdly Cheap Right Now
Looking for value in today's pricy market? These three stocks fit the bill.
5 Key Things You Should Watch With Jazz Pharmaceuticals
Jazz Pharmaceuticals' CEO says that these developments are what investors should closely monitor in the months ahead.
Why Movado Group, Catalent, and ImmunoGen Jumped Today
On a positive day for the major benchmarks, these stocks gained. Find out why.